Susceptibility of Patients with Asthma to a Poor Outcome of COVID-19.
作者信息
Persson Carl
机构信息
University Hospital of Lund Lund, Sweden.
出版信息
Am J Respir Crit Care Med. 2022 Oct 1;206(7):922-923. doi: 10.1164/rccm.202205-0978LE.
Abstract
摘要
相似文献
1
Susceptibility of Patients with Asthma to a Poor Outcome of COVID-19.
Am J Respir Crit Care Med. 2022 Oct 1;206(7):922-923. doi: 10.1164/rccm.202205-0978LE.
2
Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study.过敏疾病与 COVID-19 的易感性和严重程度：一项全国性队列研究。
J Allergy Clin Immunol. 2020 Oct;146(4):790-798. doi: 10.1016/j.jaci.2020.08.008. Epub 2020 Aug 15.
3
Asthma and COVID-19 pandemic: focus on the eosinophil count and ACE2 expression.哮喘与 COVID-19 大流行：关注嗜酸性粒细胞计数和 ACE2 表达。
Eur Ann Allergy Clin Immunol. 2022 Nov;54(6):284-289. doi: 10.23822/EurAnnACI.1764-1489.233. Epub 2021 Sep 10.
4
The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19.过敏和哮喘作为合并症对 COVID-19 的易感性和结局的影响。
Int Immunol. 2022 Mar 25;34(4):177-188. doi: 10.1093/intimm/dxab107.
5
[Asthma and COVID-19].[哮喘与2019冠状病毒病]
Rev Alerg Mex. 2022;69 Suppl 1:s15-s23. doi: 10.29262/ram.v69iSupl1.1009.
6
SARS-CoV-2-Specific Adaptive Immunity in COVID-19 Survivors With Asthma.COVID-19 幸存者哮喘患者中的 SARS-CoV-2 特异性适应性免疫。
Front Immunol. 2022 Jul 18;13:947724. doi: 10.3389/fimmu.2022.947724. eCollection 2022.
7
SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.严重哮喘患者接受生物制剂治疗后感染 SARS-CoV-2。
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2588-2595. doi: 10.1016/j.jaip.2022.05.041. Epub 2022 Jun 23.
8
ASTHMA IN A PATIENT WITH COVID-19: DOES IT PROTECT OR INCREASE THE RISKS?COVID-19 患者中的哮喘：是保护还是增加风险？
Wiad Lek. 2021;74(5):1245-1249.
9
Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease.为何 COVID-19 患者的哮喘发病率较低，这证明了将 EDTA 溶液重新用于预防和治疗 COVID-19 疾病是合理的。
Med Hypotheses. 2020 Nov;144:110027. doi: 10.1016/j.mehy.2020.110027. Epub 2020 Jun 26.
10
Susceptibility of Patients with Airway Disease to SARS-CoV-2 Infection.气道疾病患者对SARS-CoV-2感染的易感性。
Am J Respir Crit Care Med. 2022 Sep 15;206(6):696-703. doi: 10.1164/rccm.202111-2547PP.
本文引用的文献
1
Susceptibility of Patients with Airway Disease to SARS-CoV-2 Infection.气道疾病患者对SARS-CoV-2感染的易感性。
Am J Respir Crit Care Med. 2022 Sep 15;206(6):696-703. doi: 10.1164/rccm.202111-2547PP.
2
Early humoral defense under the radar: microvascular-epithelial cooperation at airways infection in asthma and health.未被察觉的早期体液防御：哮喘及健康状态下气道感染时微血管与上皮细胞的协作
Am J Physiol Lung Cell Mol Physiol. 2022 Mar 1;322(3):L503-L506. doi: 10.1152/ajplung.00470.2021.
3
'Bedside' observations challenge aspects of the 'epithelial barrier hypothesis'.“床边”观察对“上皮屏障假说”的各个方面提出了挑战。
Nat Rev Immunol. 2021 Dec;21(12):829. doi: 10.1038/s41577-021-00650-8.
4
Cross-linked fibrin in the nasal fluid of patients with the common cold.普通感冒患者鼻腔分泌物中的交联纤维蛋白。
Clin Infect Dis. 2002 Mar 1;34(5):708-10. doi: 10.1086/338716. Epub 2002 Jan 25.
5
Oral prednisone therapy in experimental rhinovirus infections.实验性鼻病毒感染中的口服泼尼松治疗
J Allergy Clin Immunol. 1996 Apr;97(4):1009-14. doi: 10.1016/s0091-6749(96)80077-7.
6
Protein content in bronchoalveolar lavage fluid of patients with asthma and control subjects.
J Allergy Clin Immunol. 1995 Jan;95(1 Pt 1):60-8. doi: 10.1016/s0091-6749(95)70153-2.
Zotero 插件